Publications by authors named "K Masubuchi"
Background: Molluscum contagiosum (MC) is a contagious viral skin infection. Berdazimer gel, 10.3% (SB206 12%) is approved in the United States as the first topical, at-home MC prescription medication.
View Article and Find Full Text PDFBackground: The standard treatment for patients in good general condition with limited-disease small cell lung cancer (LD-SCLC) is concurrent platinum/etoposide chemotherapy and thoracic radiotherapy (TRT). However, the efficacy and safety of chemoradiotherapy (CRT) in older patients with LD-SCLC has not been fully explored; moreover, the optimal treatment for this patient group remains unclear. This study aimed to investigate the feasibility and efficacy of CRT in older patients with LD-SCLC.
View Article and Find Full Text PDFArticle Synopsis
- * A retrospective analysis of 124 LD-SCLC patients revealed that those with favorable GPS scores (0-1) experienced significantly better progression-free survival (PFS) and overall survival (OS) compared to those with unfavorable scores (GPS 2).
- * The study suggests that the GPS may serve as a useful tool for predicting treatment outcomes in LD-SCLC, with favorable scores correlating with improved survival rates.
Article Synopsis
- Pembrolizumab combined with platinum and pemetrexed (Pemb-Plt-PEM) is a promising first-line treatment for advanced non-squamous non-small-cell lung cancer (NSCLC), effective regardless of PD-L1 expression.
- A study assessed this treatment's safety and efficacy in elderly patients (75 years and older) who received Pemb-Plt-PEM in Japan, focusing on patient responses and adverse events.
- Results showed a 40% overall response rate and a median overall survival of 24 months, indicating that Pemb-Plt-PEM is both effective and feasible for treating non-squamous NSCLC in older patients.
Article Synopsis
- Mirtazapine, when combined with granisetron and dexamethasone, was studied for preventing nausea and vomiting caused by carboplatin in patients with thoracic cancers.
- A trial involving 52 patients showed high rates of complete response—83.3% during the delayed phase (24-120 hours) and 100% in the acute phase (0-24 hours)—with minimal side effects.
- Results suggest that this three-drug combination is effective and safe for patients undergoing chemotherapy with carboplatin at specified dosages.